Therapeutic potential of cannabis-related drugs

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 157-166

  Alexander, Stephen P H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cannabinoids; Drugs of abuse; Therapeutic potential

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; BACLOFEN; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; FATTY ACID AMIDASE; G PROTEIN COUPLED RECEPTOR; N (3 PYRIDAZINYL) 4 [3 (5 TRIFLUOROMETHYL 2 PYRIDINYLOXY)BENZYLIDENE] 1 PIPERIDINECARBOXAMIDE; N ACYLETHANOLAMINE ACID AMIDASE; NABIXIMOLS; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; CANNABINOID;

ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIEMETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; BRAIN FUNCTION; CANNABIS ADDICTION; CANNABIS USE; CHEMICAL STRUCTURE; CHRONIC PAIN; CORPUS STRIATUM; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; EPILEPSY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEEDING DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLAUCOMA; GLIOBLASTOMA; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; INFLAMMATORY PAIN; METABOLIC REGULATION; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NERVE DEGENERATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OSTEOARTHRITIS; PARKINSON DISEASE; PREFRONTAL CORTEX; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; STRESS; SUICIDAL IDEATION; TRANQUILIZING ACTIVITY; ANIMAL; CHEMISTRY; METABOLISM; PHYTOTHERAPY;

ANIMALS; CANNABINOIDS; CANNABIS; ENDOCANNABINOIDS; HUMANS; MARIJUANA ABUSE; PHYTOTHERAPY;

EID: 84941168596     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.07.001     Document Type: Review

References (130)

1. Alexander S.P.H., Kendall D.A. The complications of promiscuity: endocannabinoid action and metabolism. Br. J. Pharmacol. 2007, 152:602-623.
2. Arnone M., Maruani J., Chaperon F., Thiébot M.-H., Poncelet M., Soubrié P., Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997, 132:104-106.
3. Atwood B.K., Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol. 2010, 160:467-479.
4. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84-87.
5. Ball S., Vickery J., Hobart J., Wright D., Green C., Shearer J., Nunn A., Gomez C.M., Macmanus D., Miller D., Mallik S., Zajicek J. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol. Assess. 2015, 19:1-188.
6. Bandiera T., Ponzano S., Piomelli D. Advances in the discovery of N-acylethanolamine acid amidase inhibitors. Pharmacol. Res. 2014, 86:11-17.
7. Bhattacharyya S., Crippa J.A., Allen P., Martin-Santos R., Borgwardt S., Fusar-Poli P., Rubia K., Kambeitz J., O'Carroll C., Seal M.L., Giampietro V., Brammer M., Zuardi A.W., Atakan Z., McGuire P.K. Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch. Gen. Psychiatry 2012, 69:27-36.
8. Blankman J.L., Simon G.M., Cravatt B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol. 2007, 14:1347-1356.
9. Bluett R.J., Gamble-George J.C., Hermanson D.J., Hartley N.D., Marnett L.J., Patel S. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. Transl. Psychiatry 2014, 4:e408.
10. Bolognini D., Rock E., Cluny N., Cascio M., Limebeer C., Duncan M., Stott C., Javid F., Parker L., Pertwee R. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT(1A) receptor activation. Br. J. Pharmacol. 2013, 168:1456-1470.
11. Burston J.J., Woodhams S.G. Endocannabinoid system and pain: an introduction. Proc. Nutr. Soc. 2014, 73:106-117.
12. Castaneto M.S., Gorelick D.A., Desrosiers N.A., Hartman R.L., Pirard S., Huestis M.A. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014, 144:12-41.
13. Console-Bram L., Brailoiu E., Brailoiu G.C., Sharir H., Abood M.E. Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br. J. Pharmacol. 2014, 171:3908-3917.
14. Cridge B.J., Rosengren R.J. Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag. Res. 2013, 5:301-313.
15. Cross-Mellor S.K., Ossenkopp K.P., Piomelli D., Parker L.A. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology 2007, 190:135-143.
16. Darmani N.A. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur. J. Pharmacol. 2001, 430:49-58.
17. Davenport A.P., Alexander S.P.H., Sharman J.L., Pawson A.J., Benson H.E., Monaghan A.E., Liew W.C., Mpamhanga C.P., Bonner T.I., Neubig R.R., Pin J.-P., Spedding M., Harmar A.J. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol. Rev. 2013, 65:967-986.
18. De Petrocellis L., Ligresti A., Moriello A.S., Allara M., Bisogno T., Petrosino S., Stott C.G., Di Marzo V. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 2011, 163:1479-1494.
19. De Petrocellis L., Orlando P., Moriello A.S., Aviello G., Stott C., Izzo A.A., Di Marzo V. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf.) 2012, 204:255-266.
20. Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C., Katz R., Di Marzo V., Jutras-Aswad D., Notcutt W.G., Martinez-Orgado J., Robson P.J., Rohrback B.G., Thiele E., Whalley B., Friedman D. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014, 55:791-802.
21. Dincheva I., Drysdale A.T., Hartley C.A., Johnson D.C., Jing D., King E.C., Ra S., Gray J.M., Yang R., DeGruccio A.M., Huang C., Cravatt B.F., Glatt C.E., Hill M.N., Casey B.J., Lee F.S. FAAH genetic variation enhances fronto-amygdala function in mouse and human. Nat. Commun. 2015, 6:6395.
22. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10819-10824.
23. Downer E.J., Clifford E., Amu S., Fallon P.G., Moynagh P.N. The synthetic cannabinoid R(+)WIN55,212-2 augments interferon-beta expression via peroxisome proliferator-activated receptor-alpha. J. Biol. Chem. 2012, 287:25440-25453.
24. Durinck S., Stawiski E.W., Pavia-Jimenez A., Modrusan Z., Kapur P., Jaiswal B.S., Zhang N., Toffessi-Tcheuyap V., Nguyen T.T., Pahuja K.B., Chen Y.J., Saleem S., Chaudhuri S., Heldens S., Jackson M., Pena-Llopis S., Guillory J., Toy K., Ha C., Harris C.J., Holloman E., Hill H.M., Stinson J., Rivers C.S., Janakiraman V., Wang W., Kinch L.N., Grishin N.V., Haverty P.M., Chow B., Gehring J.S., Reeder J., Pau G., Wu T.D., Margulis V., Lotan Y., Sagalowsky A., Pedrosa I., de Sauvage F.J., Brugarolas J., Seshagiri S. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat. Genet. 2015, 47:13-21.
25. Elmes M.W., Kaczocha M., Berger W.T., Leung K., Ralph B.P., Wang L., Sweeney J.M., Miyauchi J.T., Tsirka S.E., Ojima I., Deutsch D.G. Fatty acid binding proteins (FABPs) are intracellular carriers for delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J. Biol. Chem. 2015, 290:8711-8721.
26. England T.J., Hind W.H., Rasid N.A., O'Sullivan S.E. Cannabinoids in experimental stroke: a systematic review and meta-analysis. J. Cereb. Blood Flow Metab. 2015, 35:348-358.
27. Fagan S.G., Campbell V.A. The influence of cannabinoids on generic traits of neurodegeneration. Br. J. Pharmacol. 2014, 171:1347-1360.
28. Farkas S., Nagy K., Palkovits M., Kovacs G.G., Jia Z., Donohue S., Pike V., Halldin C., Mathe D., Harkany T., Gulyas B., Csiba L. [125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease. Neurochem. Int. 2011, 60:286-291.
29. Felder C.C., Joyce K.E., Briley E.M., Glass M., Mackie K.P., Fahey K.J., Cullinan G.J., Hunden D.C., Johnson D.W., Chaney M.O., Koppel G.A., Brownstein M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 1998, 284:291-297.
30. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48:443-450.
31. Feliu A., Moreno-Martet M., Mecha M., Carrillo-Salinas F.J., de Lago E., Fernandez-Ruiz J., Guaza C. A Sativex-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br. J. Pharmacol. 2015, 172:3579-3595.
32. Fowler C.J. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br. J. Pharmacol. 2007, 152:594-601.
33. Fowler C.J. Monoacylglycerol lipase - a target for drug development?. Br. J. Pharmacol. 2012, 166:1568-1585.
34. Fowler C.J. Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J. 2013, 280:1895-1904.
35. Fowler C.J., Jonsson K.O., Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem. Pharmacol. 2001, 62:517-526.
36. Fowler C.J., Naidu P.S., Lichtman A., Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br. J. Pharmacol. 2009, 156:412-419.
37. Galve-Roperh I., Sanchez C., Cortes M.L. Gomez del Pulgar, T., Izquierdo, M., and Guzman, M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation Nat Med 2000, 6(3):313-319. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=PM:10700234.
38. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of active constituent of hashish. J. Am. Chem. Soc. 1964, 86:1646-1647.
39. Garcia M.C., Cinquina V., Palomo-Garo C., Rabano A., Fernandez-Ruiz J. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson's disease. Neurosci. Lett. 2015, 587:1-4.
40. Glass M., Faull R.L., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience 1993, 56:523-527.
41. Gloss D., Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst. Rev. 2014, 3:CD009270.
42. Guindon J., Hohmann A.G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol. 2008, 153:319-334.
43. Guzman M., Duarte M.J., Blazquez C., Ravina J., Rosa M.C., Galve-Roperh I., Sanchez C., Velasco G., Gonzalez-Feria L. A pilot clinical study of δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer 2006, 95:197-203.
44. Hansen K.B., Rosenkilde M.M., Knop F.K., Wellner N., Diep T.A., Rehfeld J.F., Andersen U.B., Holst J.J., Hansen H.S. 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J. Clin. Endocrinol. Metab. 2011, 96:E1409-E1417.
45. Hao S.Z., Avraham Y., Mechoulam R., Berry E.M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur. J. Pharmacol. 2000, 392:147-156.
46. Hashimotodani Y., Ohno-Shosaku T., Maejima T., Fukami K., Kano M. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. Neuropharmacol 2008, 54:58-67.
47. Hashimotodani Y., Ohno-Shosaku T., Tanimura A., Kita Y., Sano Y., Shimizu T., Di Marzo V., Kano M. Acute inhibition of diacylglycerol lipase blocks endocannabinoid-mediated retrograde synaptic suppression: evidence for on-demand biosynthesis of 2-arachidonoylglycerol. J. Physiol. 2013, 591:4765-4776.
48. Henstridge C.M., Balenga N.A.B., Ford L.A., Ross R.A., Waldhoer M., Irving A.J. The GPR55 ligand L-α-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. 2009, 23:183-193.
49. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1932-1936.
50. Hillard C.J., Manna S., Greenberg M.J., Dicamelli R., Ross R.A., Stevenson L.A., Murphy V., Pertwee R.G., Campbell W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther. 1999, 289:1427-1433.
51. Hilliard A., Stott C., Wright S., Guy G., Pryce G., Al-Izki S., Bolton C., Giovannoni G. Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: a model of multiple sclerosis. ISRN Neurol. 2012, 2012:802649.
52. Hollister L.E. Health aspects of cannabis. Pharmacol. Rev. 1986, 38:1-20.
53. Howlett A.C., Johnson M.R., Melvin L.S., Milne G.M. Nonclassical cannabinoid analgetics inhibit adenylate-cyclase: development of a cannabinoid receptor model. Mol. Pharmacol. 1988, 33:297-302.
54. Huffman J.W., Liddle J., Yu S., Aung M.M., Abood M.E., Wiley J.L., Martin B.R. 3-(1',1'-Dimethylbutyl)-1-deoxy-δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 1999, 7:2905-2914.
55. Huggins J.P., Smart T.S., Langman S., Taylor L., Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012, 153:1837-1846.
56. Iannotti F.A., Hill C.L., Leo A., Alhusaini A., Soubrane C., Mazzarella E., Russo E., Whalley B.J., Di Marzo V., Stephens G.J. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem. Neurosci. 2014, 5:1131-1141.
57. Iseger T.A., Bossong M.G. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr. Res. 2015, 162:153-161.
58. Jhaveri M.D., Richardson D., Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 2007, 152:624-632.
59. Jhaveri M.D., Richardson D., Robinson I., Garle M.J., Patel A., Sun Y., Sagar D.R., Bennett A.J., Alexander S.P.H., Kendall D.A., Barrett D.A., Chapman V. Inhibition of fatty acid amide hydrolase and cycloxygenase-2 increases levels of endocannabinoids and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 2008, 55:85-93.
60. Jin K.L., Mao X.O., Goldsmith P.C., Greenberg D.A. CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 2000, 48:257-261.
61. Kaczocha M., Glaser S.T., Chae J., Brown D.A., Deutsch D.G. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J. Biol. Chem. 2010, 285:2795-2806.
62. Kaczocha M., Glaser S.T., Deutsch D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6375-6380.
63. Kang S.U. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119. Drug Discov. Today 2013, 18:1309-1315.
64. Kapur A., Zhao P., Sharir H., Bai Y., Caron M.G., Barak L.S., Abood M.E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 2009, 284:29817-29827.
65. Kirkham T.C., Williams C.M., Fezza F., Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. 2002, 136:550-557.
66. Kleberg K., Hassing H.A., Hansen H.S. Classical endocannabinoid-like compounds and their regulation by nutrients. Biofactors 2014, 40:363-372.
67. Kohno M., Hasegawa H., Inoue A., Muraoka M., Miyazaki T., Oka K., Yasukawa M. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun. 2006, 347:827-832.
68. Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G., Gloss D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014, 82:1556-1563.
69. Kramer J.L. Medical marijuana for cancer. CA Cancer J. Clin. 2015, 65:109-122.
70. Lan R.X., Liu Q., Fan P.S., Lin S.Y., Fernando S.R., McCallion D., Pertwee R., Makriyannis A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42:769-776.
71. Ledent C., Valverde O., Cossu C., Petitet F., Aubert L.F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283:401-404.
72. Limebeer C.L., Rock E.M., Mechoulam R., Parker L.A. The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex. Br. J. Pharmacol. 2012, 167:1126-1136.
73. Liu J., Li H., Burstein S.H., Zurier R.B., Chen J.D. Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid. Mol. Pharmacol. 2003, 63:983-992.
74. Long J.Z., Li W., Booker L., Burston J.J., Kinsey S.G., Schlosburg J.E., Pavon F.J., Serrano A.M., Selley D.E., Parsons L.H., Lichtman A.H., Cravatt B.F. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat. Chem. Biol. 2009, 5:37-44.
75. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 1991, 40:471-478.
76. Martin-Sanchez E., Furukawa T.A., Taylor J., Martin J.L. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009, 10:1353-1368.
77. Massi P., Solinas M., Cinquina V., Parolaro D. Cannabidiol as potential anticancer drug. Br. J. Clin. Pharmacol. 2013, 75:303-312.
78. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
79. McHugh D., Page J., Dunn E., Bradshaw H.B. δ9-THC and N-arachidonyl glycine are full agonists at GPR18 and cause migration in the human endometrial cell line, HEC-1B. Br. J. Pharmacol. 2012, 165:2414-2424.
80. McLoughlin B.C., Pushpa-Rajah J.A., Gillies D., Rathbone J., Variend H., Kalakouti E., Kyprianou K. Cannabis and schizophrenia. Cochrane Database Syst. Rev. 2014, 10:CD004837.
81. McPartland J.M., Duncan M., Di Marzo V., Pertwee R.G. Are cannabidiol and δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol. 2015, 172:737-753.
82. Mechoulam R., Hanus L.O., Pertwee R., Howlett A.C. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat. Rev. Neurosci. 2014, 15:757-764.
83. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., Pistis M. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J. Neurosci. 2008, 28:13985-13994.
84. Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 2006, 58:726-741.
85. Mor M., Rivara S., Lodola A., Plazzi P.V., Tarzia G., Duranti A., Tontini A., Piersanti G., Kathuria S., Piomelli D. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J. Med. Chem. 2004, 47:4998-5008.
86. Moulle V.S., Cansell C., Luquet S., Cruciani-Guglielmacci C. The multiple roles of fatty acid handling proteins in brain. Front. Physiol. 2012, 3:385.
87. Mulvihill M.M., Nomura D.K. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2013, 92:492-497.
88. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
89. Novotna A., Mares J., Ratcliffe S., Novakova I., Vachova M., Zapletalova O., Gasperini C., Pozzilli C., Cefaro L., Comi G., Rossi P., Ambler Z., Stelmasiak Z., Erdmann A., Montalban X., Klimek A., Davies P. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 2011, 18:1122-1131.
90. O'Sullivan S.E. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br. J. Pharmacol. 2007, 152:576-582.
91. O'Sullivan S.E., Sun Y., Bennett A.J., Randall M.D., Kendall D.A. Time-dependent vascular actions of cannabidiol in the rat aorta. Eur. J. Pharmacol. 2009, 612:61-68.
92. O'Sullivan S.E., Tarling E.J., Bennett A.J., Kendall D.A., Randall M.D. Novel time-dependent vascular actions of δ9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor γ. Biochem. Biophys. Res. Commun. 2005, 337:824-831.
93. Oka S., Toshida T., Maruyama K., Nakajima K., Yamashita A., Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem. 2009, 145:13-20.
94. Okine B.N., Norris L.M., Woodhams S., Burston J., Patel A., Alexander S.P.H., Barrett D.A., Kendall D.A., Bennett A.J., Chapman V. Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br. J. Pharmacol. 2012, 167:627-640.
95. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C., Gardner L.S., Griffin G., Jackson H.C., Procter M.J., Rasamison C.M., Tang-Christensen M., Widdowson P.S., Williams G.M., Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006, 3:167-175.
96. Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., Sagredo O., Benito C., Romero J., Azcoitia I., Fernandez-Ruiz J., Guzman M., Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
97. Parmentier-Batteur S., Jin K., Mao X.O., Xie L., Greenberg D.A. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. 2002, 22:9771-9775.
98. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P.H., Di Marzo V., Elphick M.R., Greasley P.J., Hansen H.S., Kunos G., Mackie K., Mechoulam R., Ross R.A. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 2010, 62:588-631.
99. Porcella A., Maxia C., Gessa G.L., Pani L. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur. J. Neurosci. 2000, 12:1123-1127.
100. Porcella A., Maxia C., Gessa G.L., Pani L. The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 2001, 13:409-412.
101. Ramirez B.G., Blazquez C., Gomez Del Pulgar T., Guzman M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci. 2005, 25:1904-1913.
102. Rea K., Roche M., Finn D.P. Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br. J. Pharmacol. 2007, 152:633-648.
103. Richfield E.K., Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 1994, 36:577-584.
104. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Breliere J.C., Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 1995, 56:1941-1947.
105. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.-M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Brelière J.-C., Le Fur G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 1998, 284:644-650.
106. Roques B.P., Fournie-Zaluski M.C., Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat. Rev. Drug Discov. 2012, 11:292-310.
107. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009, 30:156-163.
108. Ross R.A., Brockie H.C., Stevenson L.A., Murphy V.L., Templeton F., Makriyannis A., Pertwee R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol. 1999, 126:665-672.
109. Russo E.B. History of cannabis and its preparations in saga, science, and sobriquet. Chem. Biodivers. 2007, 4:1614-1648.
110. Russo M., Calabro R.S., Naro A., Sessa E., Rifici C., D'Aleo G., Leo A., De Luca R., Quartarone A., Bramanti P. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast. 2015, 2015:656582.
111. Ryberg E., Larsson N., Sjogren S., Hjorth S., Hermansson N.O., Leonova J., Elebring T., Nilsson K., Drmota T., Greasley P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152:1092-1101.
112. Sagar D.R., Burston J.J., Woodhams S.G., Chapman V. Dynamic changes to the endocannabinoid system in models of chronic pain. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367:3300-3311.
113. Sagar D.R., Kendall D.A., Chapman V. Inhibition of fatty acid amide hydrolase produces PPAR-α-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol. 2008, 155:1297-1306.
114. Schmid P.C., Zuzarte-Augustin M.L., Schmid H.H. Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 1985, 260:14145-14149.
115. Schroeder F., Petrescu A.D., Huang H., Atshaves B.P., McIntosh A.L., Martin G.G., Hostetler H.A., Vespa A., Landrock D., Landrock K.K., Payne H.R., Kier A.B. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids 2008, 43:1-17.
116. Sticht M.A., Long J.Z., Rock E.M., Limebeer C.L., Mechoulam R., Cravatt B.F., Parker L.A. Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br. J. Pharmacol. 2012, 165:2425-2435.
117. Storch J., Thumser A.E. Tissue-specific functions in the fatty acid-binding protein family. J. Biol. Chem. 2010, 285:32679-32683.
118. Sun Y.X., Tsuboi K., Zhao L.Y., Okamoto Y., Lambert D.M., Ueda N. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim. Biophys. Acta 2005, 1736:211-220.
119. Ueda N., Yamanaka K., Terasawa Y., Yamamoto S. An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Lett. 1999, 454:267-270.
120. Urquhart P., Nicolaou A., Woodward D.F. Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases. Biochim. Biophys. Acta 2015, 1851:366-376.
121. van Bakel H., Stout J.M., Cote A.G., Tallon C.M., Sharpe A.G., Hughes T.R., Page J.E. The draft genome and transcriptome of Cannabis sativa. Genome Biol. 2011, 12:R102.
122. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
123. Van Laere K., Casteels C., Lunskens S., Goffin K., Grachev I.D., Bormans G., Vandenberghe W. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol. Aging 2012, 33:620.e1.
124. Vara D., Morell C., Rodriguez-Henche N., Diaz-Laviada I. Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis. 2013, 4:e618.
125. Wei B.Q., Mikkelsen T.S., McKinney M.K., Lander E.S., Cravatt B.F. A second fatty acid amide hydrolase with variable distribution among placental mammals. J. Biol. Chem. 2006, 281:36569-36578.
126. Whibley A.C., Plagnol V., Tarpey P.S., Abidi F., Fullston T., Choma M.K., Boucher C.A., Shepherd L., Willatt L., Parkin G., Smith R., Futreal P.A., Shaw M., Boyle J., Licata A., Skinner C., Stevenson R.E., Turner G., Field M., Hackett A., Schwartz C.E., Gecz J., Stratton M.R., Raymond F.L. Fine-scale survey of X chromosome copy number variants and indels underlying intellectual disability. Am. J. Hum. Genet. 2010, 87:173-188.
127. Wiley J.L., Burston J.J., Leggett D.C., Alekseeva O.O., Razdan R.K., Mahadevan A., Martin B.R. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br. J. Pharmacol. 2005, 145:293-300.
128. Yazulla S. Endocannabinoids in the retina: from marijuana to neuroprotection. Prog. Retin. Eye Res. 2008, 27:501-526.
129. Yoshida T., Fukaya M., Uchigashima M., Miura E., Kamiya H., Kano M., Watanabe M. Localization of diacylglycerol lipase-α around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. J. Neurosci. 2006, 26:4740-4751.
130. Zachariou M., Alexander S.P.H., Coombes S., Christodoulou C. A biophysical model of endocannabinoid-mediated short term depression in hippocampal inhibition. PLoS One 2013, 8:e5892.